Cisatracurium besilate

Cisatracurium besilate
Clinical data
Trade names	Nimbex
Other names	51W89, cisatracurium besylate (USAN US)
AHFS/Drugs.com	Monograph
License data	US DailyMed: Cisatracurium_besylate;
Pregnancy; category	AU: C;
Routes of; administration	Intravenous
ATC code	M03AC11 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	100% (IV)
Metabolism	80% Hofmann degradation/ liver
Elimination half-life	20–29 minutes
Excretion	10-15% unchanged
Identifiers
	IUPAC name 5-[3-[(1R,2R)-1-[(3,4-Dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-yl]propanoyloxy]pentyl 3-[(1R,2R)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-yl]propanoate benzenesulfonate (1:2);
CAS Number	96946-42-8 ; 96946-41-7;
PubChem CID	62886; 62887;
DrugBank	DBSALT002671 ; DB00565;
ChemSpider	56614 ; 56615;
UNII	80YS8O1MBS; QX62KLI41N;
KEGG	D00759;
ChEBI	CHEBI:3721 ; CHEBI:140621;
ChEMBL	ChEMBL1200641 ; ChEMBL1201248;
CompTox Dashboard (EPA)	DTXSID10895045 ;
ECHA InfoCard	100.149.509
Chemical and physical data
Formula	C65H82N2O18S2
Molar mass	1243.49 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [O-]S(=O)(=O)c1ccccc1.[O-]S(=O)(=O)c1ccccc1.O=C(OCCCCCOC(=O)CC[N@@+]2([C@@H](c1c(cc(OC)c(OC)c1)CC2)Cc3ccc(OC)c(OC)c3)C)CC[N@+]5(C)[C@@H](c4cc(OC)c(OC)cc4CC5)Cc6ccc(OC)c(OC)c6;
	InChI InChI=1S/C53H72N2O12.2C6H6O3S/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6;27-10(8,9)6-4-2-1-3-5-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3;21-5H,(H,7,8,9)/q+2;;/p-2/t42-,43-,54-,55-;;/m1../s1 ; Key:XXZSQOVSEBAPGS-DONVQRBFSA-L ;
	(what is this?) (verify)

Cisatracurium besilate (INN; cisatracurium besylate (USAN); formerly recognized as 51W89; trade name Nimbex) is a bisbenzyltetrahydroisoquinolinium that has effect as a neuromuscular-blocking drug non-depolarizing neuromuscular-blocking drugs, used adjunctively in anesthesia to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. It shows intermediate duration of action. Cisatracurium is one of the ten isomers of the parent molecule, atracurium. Moreover, cisatracurium represents approximately 15% of the atracurium mixture.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.